Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$589.99 USD

589.99
674,764

+4.25 (0.73%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $590.28 +0.29 (0.05%) 6:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises

Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up

Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down

Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.

Reasons to Retain Patterson Companies (PDCO) Stock Now

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

3 Reasons Why Growth Investors Shouldn't Overlook McKesson (MCK)

McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Should Value Investors Buy Henry Schein (HSIC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Integer Holdings (ITGR) Q4 Earnings Beat Estimates, Margins Up

Integer Holdings' (ITGR) fourth-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.

PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top

Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.

Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.

Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down

Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).

Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up

Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.

AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates

Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips

Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.

Shockwave Medical's (SWAV) Q4 Earnings Top, Revenues Surge Y/Y

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

QuidelOrtho (QDEL) Q4 Earnings Top Estimates, Margins Down

QuidelOrtho (QDEL) reports robust overall top-line results in fourth-quarter 2022, despite disappointing segmental and geographical performances on a reported basis.

LabCorp (LH) Q4 Earnings Surpass Estimates, Margins Fall

The severe foreign exchange headwind, inflationary pressure and the ongoing Ukraine/Russia crisis impact LabCorp's (LH) business performance in Q4.

Henry Schein (HSIC) Q4 Earnings In Line, Gross Margin Up

Growth in Technology and Value-added Services and the Medical segment drove Henry Schein's (HSIC) Q4 revenues.

West Pharmaceutical (WST) Q4 Earnings Beat, Order Book Strong

West Pharmaceutical's (WST) fourth-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.

McKesson (MCK) Announces Availability of FDA-Cleared Drug for MCL

The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for MCL.

Ecolab (ECL) Q4 Earnings & Revenues Beat, Margins Decline

Ecolab's (ECL) robust performance across all segments drives its Q4 sales despite business challenges.